These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35525551)

  • 1. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
    Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
    Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.
    Choi BK; Cai X; Yuan B; Huang Z; Fan X; Deng H; Zhang N; An Z
    Protein Cell; 2012 Oct; 3(10):781-9. PubMed ID: 22983903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small molecule inhibitor of HER3: a proof-of-concept study.
    Colomba A; Fitzek M; George R; Weitsman G; Roberts S; Zanetti-Domingues L; Hirsch M; Rolfe DJ; Mehmood S; Madin A; Claus J; Kjaer S; Snijders AP; Ng T; Martin-Fernandez M; Smith DM; Parker PJ
    Biochem J; 2020 Sep; 477(17):3329-3347. PubMed ID: 32815546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
    Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
    J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers.
    Choi B; Cha M; Eun GS; Lee DH; Lee S; Ehsan M; Chae PS; Heo WD; Park Y; Yoon TY
    Elife; 2020 Apr; 9():. PubMed ID: 32267234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of inhibition effect of herceptin on interaction between heregulin and erbB receptors HER3/HER2 by single-molecule force spectroscopy.
    Shi X; Xu L; Yu J; Fang X
    Exp Cell Res; 2009 Oct; 315(16):2847-55. PubMed ID: 19497323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.
    Campbell MR; Ruiz-Saenz A; Peterson E; Agnew C; Ayaz P; Garfinkle S; Littlefield P; Steri V; Oeffinger J; Sampang M; Shan Y; Shaw DE; Jura N; Moasser MM
    Cell Rep; 2022 Feb; 38(5):110291. PubMed ID: 35108525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
    Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
    Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.
    Claus J; Patel G; Autore F; Colomba A; Weitsman G; Soliman TN; Roberts S; Zanetti-Domingues LC; Hirsch M; Collu F; George R; Ortiz-Zapater E; Barber PR; Vojnovic B; Yarden Y; Martin-Fernandez ML; Cameron A; Fraternali F; Ng T; Parker PJ
    Elife; 2018 May; 7():. PubMed ID: 29712619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.
    Chen CH; Chernis GA; Hoang VQ; Landgraf R
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9226-31. PubMed ID: 12874383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
    Majumder A
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms.
    van Lengerich B; Agnew C; Puchner EM; Huang B; Jura N
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2836-E2845. PubMed ID: 28320942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
    Shankaran H; Zhang Y; Tan Y; Resat H
    PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.